Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Reblozyl
Pharma
BMS has a plan to reinvigorate recent drug launches
On outgoing CEO Giovanni Caforio’s last earnings call, BMS had some tough questions to answer about a roster of underperforming new products.
Fraiser Kansteiner
Oct 26, 2023 11:45am
BMS aims for staggering 25 label expansions in the coming years
Sep 15, 2023 12:04pm
BMS' Reblozyl, chasing $4B sales target, wins key FDA expansion
Aug 29, 2023 11:23am
With Revlimid sales down, BMS slashes 2023 revenue projection
Jul 27, 2023 11:43am
ASCO: BMS' $4B plan for Reblozyl takes shape—with one caveat
May 25, 2023 5:00pm
BMS scores a topline treat in Reblozyl phase 3 study
Oct 31, 2022 12:00pm